The effect of adjusting for baseline hypoglycemia when analyzing hypoglycemia data: A systematic analysis of 15 diabetes clinical trials

Diabetes Technology and Therapeutics

Volumn 15, Issue 8, 2013, Pages 654-661

  Luo, Junxiang ^a   Jacober, Scott J ^a   Prince, Melvin J ^a   Carey, Michelle A ^b   Qu, Yongming ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Ventiv Health Clinical   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ADULT; AGED; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SLEEP; TIME FACTORS;

EID: 84882273956     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0332     Document Type: Article

References (25)

1. Cryer PE: Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:42-46
2. Davis S, Alonso MD: Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 2004;18:60-68
3. Wright AD, Cull CA, Macleod KM, Holman RR: Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006;20:395-401
4. Cryer PE: Hypoglycemia, functional brain failure, and brain death. J Clin Invest 2007;117:868-870
5. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-1288
6. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU: Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:1607-1619
7. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086
8. Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ: Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: A randomized, crossover study. Diabetes Care 2013;36:522-528
9. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265
10. Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP, Howey DC, Jacober SJ: A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with Type 2 diabetes. Diabetes Care 2012;35:2140- 2147
11. Luo J, Qu Y: Analysis of hypoglycemic events using negative binomial models. Pharm Stat 2013 (wileyonlinelibrary.com) doi: 10.1002/pst.1576
12. Malone JK, Wolthers T, Sun B, Gulliya K, Mattoo V: Improvement in HbA1c in patients with type 2 diabetes with Humalog- Mix 25 versus basal human insulin: A doubleblind study. J Appl Ther Res 2004;4:19-26
13. Li Y, Li Q, Li CJ, Wang CJ, Zheng YM, Issa M, Zhang J: Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70. Chin Med J (Engl) 2009;122:2540-2546
14. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S: Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-25
15. Jacober SJ, Scism-Bacon JL, Zagar AJ: A comparison of intensive mixture therapy with basal insulin therapy in insulin-nai?ve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8:448- 455
16. Galic E, Vrtovec M, Bozikov V, Schwarzenhofer M, Milicevic Z: The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. Med Sci Monit 2005; 11:P187-P192
17. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre- Ferrante B: Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005; 22:374-381
18. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group: Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: A 16-week, randomized, openlabel, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-2044
19. Reviriego J, Herz M, Roach P, The Humalog- Mix25 Spanish Study Group: Improved glycaemic control without increased risk of hypoglycaemia with a 25% insulin/lispro 75% NPL mixture twice daily compared with NPH twice daily in patients with type 2 diabetes [abstract]. J Appl Ther Res 2004;4:3-9
20. Malone JK, Beattie SD, Campaigne BN, Johnson PA, Howard AS, Milicevic Z: Therapy after single oral agent failure: Adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract 2003;62:187-195
21. Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS, Gack S, Gudat U: Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes Exp Clin Endocrinol Diabetes 2003;111:97-103
22. Herz M, Beattie SD: Initiation of Humalog- Mix25- improves glycemic control in patients with type 2 diabetes and inadequacy of oral agent combination therapy [abstract]. Diabetes Res Clin Pract 2000;50(Suppl 1):S43
23. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J: Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011;154:103-112
24. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP, DARTS/MEMO Collaboration: Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: A populationbased study. Diabet Med 2005;22:749-755
25. Miller ME, Bonds DE, Gerstein HC, Seaquist ER, Bergenstal RM, Calles-Escandon J, Childress RD, Craven TE, Cuddihy RM, Dailey G, Feinglos MN, Ismail-Beigi F, Largay JF, O'Connor PJ, Paul T, Savage PJ, Schubart UK, Sood A, Genuth S: The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study. BMJ 2010; 340:b5444